TY - JOUR
T1 - New insights into healthy ageing, inflammageing and frailty using metabolomics
AU - Abdullah, Genna
AU - Akpan, Asangaedem
AU - Phelan, Marie M.
AU - Wright, Helen L.
N1 - Publisher Copyright:
Copyright © 2024 Abdullah, Akpan, Phelan and Wright.
PY - 2024/7/9
Y1 - 2024/7/9
N2 - Human ageing is a normal process and does not necessarily result in the development of frailty. A mix of genetic, environmental, dietary, and lifestyle factors can have an impact on ageing, and whether an individual develops frailty. Frailty is defined as the loss of physiological reserve both at the physical and cellular levels, where systemic processes such as oxidative stress and inflammation contribute to physical decline. The newest “omics” technology and systems biology discipline, metabolomics, enables thorough characterisation of small-molecule metabolites in biological systems at a particular time and condition. In a biological system, metabolites—cellular intermediate products of metabolic reactions—reflect the system’s final response to genomic, transcriptomic, proteomic, epigenetic, or environmental alterations. As a relatively newer technique to characterise metabolites and biomarkers in ageing and illness, metabolomics has gained popularity and has a wide range of applications. We will give a comprehensive summary of what is currently known about metabolomics in studies of ageing, with a focus on biomarkers for frailty. Metabolites related to amino acids, lipids, carbohydrates, and redox metabolism may function as biomarkers of ageing and/or frailty development, based on data obtained from human studies. However, there is a complexity that underpins biological ageing, due to both genetic and environmental factors that play a role in orchestrating the ageing process. Therefore, there is a critical need to identify pathways that contribute to functional decline in people with frailty.
AB - Human ageing is a normal process and does not necessarily result in the development of frailty. A mix of genetic, environmental, dietary, and lifestyle factors can have an impact on ageing, and whether an individual develops frailty. Frailty is defined as the loss of physiological reserve both at the physical and cellular levels, where systemic processes such as oxidative stress and inflammation contribute to physical decline. The newest “omics” technology and systems biology discipline, metabolomics, enables thorough characterisation of small-molecule metabolites in biological systems at a particular time and condition. In a biological system, metabolites—cellular intermediate products of metabolic reactions—reflect the system’s final response to genomic, transcriptomic, proteomic, epigenetic, or environmental alterations. As a relatively newer technique to characterise metabolites and biomarkers in ageing and illness, metabolomics has gained popularity and has a wide range of applications. We will give a comprehensive summary of what is currently known about metabolomics in studies of ageing, with a focus on biomarkers for frailty. Metabolites related to amino acids, lipids, carbohydrates, and redox metabolism may function as biomarkers of ageing and/or frailty development, based on data obtained from human studies. However, there is a complexity that underpins biological ageing, due to both genetic and environmental factors that play a role in orchestrating the ageing process. Therefore, there is a critical need to identify pathways that contribute to functional decline in people with frailty.
KW - frailty
KW - healthy ageing
KW - inflammageing
KW - metabolism
KW - metabolomics
UR - http://www.scopus.com/inward/record.url?scp=85199199982&partnerID=8YFLogxK
U2 - 10.3389/fragi.2024.1426436
DO - 10.3389/fragi.2024.1426436
M3 - Review article
C2 - 39044748
AN - SCOPUS:85199199982
SN - 2673-6217
VL - 5
JO - Frontiers in Aging
JF - Frontiers in Aging
M1 - 1426436
ER -